Tiagabine Hydrochloride
NDC Package 52536-360-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Tiagabine Hydrochloride is a . Marketed by Wilshire Pharmaceuticals, Inc., this product is identified by NDC 52536-360 and is authorized under FDA application ANDA206857.

Identification & Billing

NDC Package Code
52536-360-03
Package Description
30 TABLET in 1 BOTTLE
Product Code
52536-360
11-Digit Billing Format
52536036003

Clinical Specifications

Proprietary Name
Tiagabine Hydrochloride
Dosage Form
-

Regulatory & Marketing

Labeler Name
Wilshire Pharmaceuticals, Inc.
FDA Application #
ANDA206857
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-01-2018
End Marketing Date
02-16-2021
Listing Expiration
02-16-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52536-360-03 identifies a specific commercial package of 30 tablet in 1 bottle of Tiagabine Hydrochloride, labeled by Wilshire Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Wilshire Pharmaceuticals, Inc. on June 01, 2018. The current certification is valid through February 16, 2021.

How is this Wilshire Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52536036003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52536-360-03
11-Digit CMS (5-4-2)
52536-0360-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.